[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:cholangiocarcinoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":312,"states":320},"Cholangiocarcinoma",71,58,[8,16,23,29,35,41,47,54,60,66,72,78,84,90,96,102,108,114,120,126,132,138,144,150,156,162,168,174,180,186,192,198,204,210,216,222,228,234,240,246,252,258,264,270,276,282,288,295,301,306],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05874414","Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:17:33.807405Z","2026-07-19T19:36:05.120159Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07619313","AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer",[20],"Phase 1","2026-08-26T02:16:54.044282Z","2026-06-04T01:30:07.902796Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06501625","Ivosidenib Plus Durvalumab and Gemcitabine\u002FCisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation",[12],"2026-08-26T02:16:42.787115Z","2026-05-29T15:36:40.175966Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06914648","The Dragon PLC Trial (DRAGON-PLC)",[],"2026-08-26T02:17:49.709549Z","2026-05-05T02:43:29.586465Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06160752","Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations",[20],"2026-08-03T02:40:44.217164Z","2026-05-05T02:43:29.538848Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT06439485","Phase I\u002FII Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion",[12],"2026-08-26T02:16:52.995882Z","2026-05-05T02:43:29.399905Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":52,"content_modified":53},"NCT05727176","Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement",[51],"Phase 2","2026-08-26T02:17:04.346841Z","2026-05-05T02:43:28.866322Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT06302621","Pemigatinib + Afatinib in Advanced Refractory Solid Tumors",[20],"2026-08-26T02:17:32.059863Z","2026-05-05T02:43:27.588725Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT05727787","vGRID SBRT: A Phase I Clinical Trial in Unresectable or Metastatic HCC",[],"2026-08-26T02:18:49.989941Z","2026-05-05T02:43:26.800461Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT07594067","TCR1188-ABC Cells in KRAS-mutated Cancers",[20],"2026-08-26T02:16:38.053590Z","2026-07-19T19:36:05.077181Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT03943004","Trial of DFP-14927 in Advanced Solid Tumors",[20],"2026-08-26T02:16:44.178623Z","2026-05-05T02:43:29.398880Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT05244551","A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors",[20],"2026-08-26T02:18:55.570428Z","2026-05-05T02:43:28.531183Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT06546969","Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer",[20],"2026-08-26T02:16:08.402952Z","2026-05-05T02:43:28.528917Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT05791448","AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease",[20],"2026-08-03T03:44:18.231456Z","2026-05-05T02:43:27.960862Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT05053555","High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies",[],"2026-08-26T02:15:36.077529Z","2026-05-05T02:43:27.915806Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT05286814","PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma",[51],"2026-08-26T02:15:11.740957Z","2026-05-05T02:43:27.432991Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT04645160","Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers",[12],"2026-08-26T02:15:29.632183Z","2026-05-05T02:43:27.427708Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT07382544","Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss",[20],"2026-08-26T02:16:24.970704Z","2026-05-05T02:43:26.931101Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":124,"content_modified":125},"NCT07146646","Trifluridine\u002FTipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer",[51],"2026-08-26T02:19:07.104270Z","2026-05-05T02:35:31.762112Z",{"nct_id":127,"title":128,"phases":129,"status":13,"updated_at":130,"content_modified":131},"NCT05503797","A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations",[51],"2026-08-26T02:19:21.761002Z","2026-07-30T01:46:14.464355Z",{"nct_id":133,"title":134,"phases":135,"status":13,"updated_at":136,"content_modified":137},"NCT07070232","A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors",[12],"2026-08-26T02:18:30.351130Z","2026-07-24T01:27:14.894336Z",{"nct_id":139,"title":140,"phases":141,"status":13,"updated_at":142,"content_modified":143},"NCT07186842","A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9",[12],"2026-08-26T02:15:27.567165Z","2026-07-19T19:36:05.067561Z",{"nct_id":145,"title":146,"phases":147,"status":13,"updated_at":148,"content_modified":149},"NCT06725758","A Phase 1\u002F2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours",[12],"2026-08-26T02:18:25.327036Z","2026-05-13T02:55:06.568386Z",{"nct_id":151,"title":152,"phases":153,"status":13,"updated_at":154,"content_modified":155},"NCT07050771","Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery",[51],"2026-08-26T02:18:39.640967Z","2026-05-05T02:43:29.665036Z",{"nct_id":157,"title":158,"phases":159,"status":13,"updated_at":160,"content_modified":161},"NCT07488676","A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors",[12],"2026-08-26T02:19:04.543908Z","2026-05-05T02:43:29.590211Z",{"nct_id":163,"title":164,"phases":165,"status":13,"updated_at":166,"content_modified":167},"NCT05176665","EMB-01 in Patients With Advanced\u002FMetastatic Gastrointestinal Cancers",[12],"2026-08-26T02:16:21.385056Z","2026-05-05T02:43:29.528254Z",{"nct_id":169,"title":170,"phases":171,"status":13,"updated_at":172,"content_modified":173},"NCT04421820","BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours",[12],"2026-08-26T02:18:57.189473Z","2026-05-05T02:43:29.383186Z",{"nct_id":175,"title":176,"phases":177,"status":13,"updated_at":178,"content_modified":179},"NCT07148128","Phase 1\u002F2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.",[12],"2026-08-26T02:17:28.381459Z","2026-05-05T02:43:28.963256Z",{"nct_id":181,"title":182,"phases":183,"status":13,"updated_at":184,"content_modified":185},"NCT06756035","CT-95 in Advanced Cancers Associated With Mesothelin Expression",[20],"2026-08-26T02:16:07.529922Z","2026-05-05T02:43:28.867277Z",{"nct_id":187,"title":188,"phases":189,"status":13,"updated_at":190,"content_modified":191},"NCT06840886","A Study of PHST001 in Advanced Solid Tumors",[20],"2026-08-26T02:16:12.203827Z","2026-05-05T02:43:28.622448Z",{"nct_id":193,"title":194,"phases":195,"status":13,"updated_at":196,"content_modified":197},"NCT06270706","A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors",[20],"2026-08-26T02:18:44.395098Z","2026-05-05T02:43:28.480860Z",{"nct_id":199,"title":200,"phases":201,"status":13,"updated_at":202,"content_modified":203},"NCT07282912","Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels",[51],"2026-08-26T02:19:29.119921Z","2026-05-05T02:43:28.285786Z",{"nct_id":205,"title":206,"phases":207,"status":13,"updated_at":208,"content_modified":209},"NCT07213791","A Study of LY4337713 in Participants With FAP-Positive Solid Tumors",[20],"2026-08-26T02:17:13.277148Z","2026-05-05T02:43:28.120672Z",{"nct_id":211,"title":212,"phases":213,"status":13,"updated_at":214,"content_modified":215},"NCT05732831","Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors",[12],"2026-08-26T02:18:40.612983Z","2026-05-05T02:43:27.947953Z",{"nct_id":217,"title":218,"phases":219,"status":13,"updated_at":220,"content_modified":221},"NCT05674825","Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses",[12],"2026-08-26T02:15:20.225313Z","2026-05-05T02:43:27.840688Z",{"nct_id":223,"title":224,"phases":225,"status":13,"updated_at":226,"content_modified":227},"NCT06233942","Phase 1a\u002F1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors",[20],"2026-08-26T02:16:18.872924Z","2026-05-05T02:43:27.747724Z",{"nct_id":229,"title":230,"phases":231,"status":13,"updated_at":232,"content_modified":233},"NCT04361708","Safety of Combining Irinotecan With 5-FU, Leucovorin\u002FFolinic Acid, Oxaliplatin, and Docetaxel Chemotherapies",[20],"2026-08-26T02:18:37.277498Z","2026-05-05T02:43:27.322062Z",{"nct_id":235,"title":236,"phases":237,"status":13,"updated_at":238,"content_modified":239},"NCT06399757","A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors",[12],"2026-08-03T03:48:46.663572Z","2026-05-05T02:43:27.110534Z",{"nct_id":241,"title":242,"phases":243,"status":13,"updated_at":244,"content_modified":245},"NCT05969860","At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer",[51],"2026-08-26T02:17:20.511551Z","2026-05-05T02:43:26.978986Z",{"nct_id":247,"title":248,"phases":249,"status":13,"updated_at":250,"content_modified":251},"NCT06723236","A Study of MGC028 in Participants With Advanced Solid Tumors",[20],"2026-08-26T02:16:40.941792Z","2026-05-05T02:35:31.808896Z",{"nct_id":253,"title":254,"phases":255,"status":13,"updated_at":256,"content_modified":257},"NCT05568680","SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma",[20],"2026-08-26T02:15:31.806698Z","2026-05-05T02:35:31.692599Z",{"nct_id":259,"title":260,"phases":261,"status":13,"updated_at":262,"content_modified":263},"NCT06899152","HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer",[],"2026-08-26T02:19:14.560989Z","2026-05-05T02:43:29.192698Z",{"nct_id":265,"title":266,"phases":267,"status":13,"updated_at":268,"content_modified":269},"NCT05497531","Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers",[],"2026-08-26T02:17:58.890423Z","2026-05-05T02:43:28.639917Z",{"nct_id":271,"title":272,"phases":273,"status":13,"updated_at":274,"content_modified":275},"NCT04504604","TCF-001 TRACK (Target Rare Cancer Knowledge) Study",[],"2026-08-26T02:17:22.949982Z","2026-05-05T02:43:28.349240Z",{"nct_id":277,"title":278,"phases":279,"status":13,"updated_at":280,"content_modified":281},"NCT06503146","18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection",[51],"2026-08-26T02:18:24.494016Z","2026-05-05T02:35:31.918317Z",{"nct_id":283,"title":284,"phases":285,"status":13,"updated_at":286,"content_modified":287},"NCT04753996","Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients",[],"2026-08-26T02:16:15.345907Z","2026-05-13T02:55:06.267754Z",{"nct_id":289,"title":290,"phases":291,"status":13,"updated_at":293,"content_modified":294},"NCT06622057","D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer",[292],"Phase 3","2026-08-26T02:18:26.932189Z","2026-06-14T18:39:22.251168Z",{"nct_id":296,"title":297,"phases":298,"status":13,"updated_at":299,"content_modified":300},"NCT05179486","Molecular Epidemiology of Biliary Tree Cancers",[],"2026-08-26T02:15:51.395565Z","2026-05-13T02:55:06.294011Z",{"nct_id":302,"title":303,"phases":304,"status":13,"updated_at":21,"content_modified":305},"NCT03445585","Biobank for Cholestatic Liver Diseases.",[],"2026-05-13T02:55:06.126362Z",{"nct_id":307,"title":308,"phases":309,"status":13,"updated_at":310,"content_modified":311},"NCT07224750","A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer",[],"2026-08-26T02:16:04.914942Z","2026-05-13T02:55:06.676889Z",[313,317],{"biomarker":314,"count":315,"slug":316},"Fibroblast Growth Factor Receptor 2",3,"fibroblast-growth-factor-receptor-2",{"biomarker":318,"count":315,"slug":319},"GTPase KRas","gtpase-kras",[321,325,329,333,337,341,345,348,351,355,359,363,366,369,373,376,379,382,386,389,392],{"state":322,"count":323,"slug":324},"Texas",27,"texas",{"state":326,"count":327,"slug":328},"California",25,"california",{"state":330,"count":331,"slug":332},"New York",18,"new-york",{"state":334,"count":335,"slug":336},"Florida",15,"florida",{"state":338,"count":339,"slug":340},"Michigan",12,"michigan",{"state":342,"count":343,"slug":344},"Massachusetts",11,"massachusetts",{"state":346,"count":343,"slug":347},"Ohio","ohio",{"state":349,"count":343,"slug":350},"Pennsylvania","pennsylvania",{"state":352,"count":353,"slug":354},"North Carolina",10,"north-carolina",{"state":356,"count":357,"slug":358},"Illinois",9,"illinois",{"state":360,"count":361,"slug":362},"Maryland",8,"maryland",{"state":364,"count":361,"slug":365},"Minnesota","minnesota",{"state":367,"count":361,"slug":368},"Virginia","virginia",{"state":370,"count":371,"slug":372},"Colorado",6,"colorado",{"state":374,"count":371,"slug":375},"Connecticut","connecticut",{"state":377,"count":371,"slug":378},"Tennessee","tennessee",{"state":380,"count":371,"slug":381},"Wisconsin","wisconsin",{"state":383,"count":384,"slug":385},"Missouri",5,"missouri",{"state":387,"count":384,"slug":388},"New Jersey","new-jersey",{"state":390,"count":384,"slug":391},"Utah","utah",{"state":393,"count":315,"slug":394},"Washington","washington"]